PATENT CLAIM ANALYSIS

Application Number: 16210968
Application Type: Utility
Filing Date: 2018-12
Publication Date: 2019-08
Patent Classification: ["514", "210180"]

Abstract:
The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

Claim (Index 2):
A pharmaceutical composition comprising a formula I: or a pharmaceutically acceptable salt thereof, wherein: R 1  is an optionally substituted group selected from C 3-8  cycloalkyl, 5-8 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S as ring members, phenyl, \u2014SO2-phenyl, \u2014C(O)-phenyl, \u2014C(R8)2-phenyl, and 5-6 membered heteroaryl ring, wherein said heterocyclyl and heteroaryl contain 1-2 heteroatoms selected from N, O and S as ring members, and wherein the optional substituents for R1 are 1-3 groups independently selected from D, halo, hydroxy, amino, \u2014N(R8)2, CN, C1-4 alkyl, C1-4 alkoxy, \u2014S(C1-4 alkyl), C1-4 haloalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), CN, COOR8, CON(R8)2, \u2014NR8-C(O)R8, \u2014NR8-C(O)OR8 SO2R8, \u2014NR8SO2R8, and SO2N(R8)2, where each R8 is independently H or C1-4 alkyl; L is a bond, or L can be a C1-4 alkylene, C2-4 alkenylene, C1-4 alkynylene, C3-6 cycloalkyl or a 4-7 membered heterocycloyl containing 1-2 heteroatoms selected from N, O and S as ring members, wherein L is optionally substituted with 1-3 groups independently selected from R11, D, OH, NH2, NHR11, NHC(\u2550O)R11, \u2014NHC(\u2550O)\u2014OR11, \u2014NHC(\u2550O)\u2014NH2, \u2014NHC(\u2550O)\u2014NHR11, \u2014N(R11)2, CN, halo, N3, CON(R7)2, and COOR7; where each R11 is independently C1-4 alkyl, which may be substituted with up to three groups independently selected from D, halo, OH, NH2,\u2014NHMe, \u2014NMe2, \u2014OP(O)(OH)2 and O\u2014C1-4 alkyl; X and Y are independently selected from H, D, halo, CN, amino, hydroxy, C1-4 alkyl, C1-4 haloalkyl, C1-4 alkoxy, and C1-4 haloalkoxy; R2 is H, C1-4 alkyl, or aryl-C1-2-alkyl-, wherein the aryl and C1-4 alkyl are optionally substituted with halo, CN, C1-4 alkyl, C1-4 haloalkyl, C3-6 cycloalkyl, C1-4 alkoxy, C1-4 haloalkoxy, or C1-4 alkylsulfonyl; or R2 can cyclize with X to form a 5-7 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S fused to the phenyl ring to which X is attached, or R2 can cyclize with L to form a 5-7 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S, wherein the optional heterocyclic ring formed by R2 cyclizing with X, or by R2 cyclizing with L, can be optionally substituted with one or two groups independently selected from CN, halo, C1-4 alkyl, C1-4 alkoxy, C1 4 haloalkyl, C1-4 haloalkoxy, oxo, CN, COOR7, CON(R7)2, and SO2R7; each R7 is independently H or C1-4 alkyl; Z is N or CR4; R4 is H, D, halo, C1-4 alkyl, C1-4 haloalkyl, or C1-4 alkoxy; R5 is selected from \u2014C(O)\u2014R5a and R5a; wherein R5a is an optionally substituted C3-8 cycloalkyl, C3-8 cycloalkenyl, saturated or unsaturated 3-8 membered heterocyclic ring containing 1-2 heteroatoms selected from N, O and S, phenyl, or 5-6 membered heteroaryl ring containing 1-3 heteroatoms selected from N, O and S, wherein the optional substituents for R5 are 1-4 groups independently selected from D, halo, hydroxy, amino, CN, C1-4 alkyl, C1-4 alkoxy, C1-4 haloalkyl, C1-4 hydroxyalkyl, C1-4 haloalkoxy, C3-6 cycloalkyl, 3-6 membered heterocyclyl containing 1-2 heteroatoms selected from N, O and S, oxo (except on aromatic rings), CN, \u2014COOR9, \u2014C(O)R9, CON(R9)2, \u2014NR9C(O)R9, \u2014NR9CO2R9, SO2R9, \u2014NR9SO2R9, and \u2014SO2N(R9)2, where each R9 is independently H or C1-4 alkyl optionally substituted with 1-3 groups independently selected from D, halo, OH, NH2, NHMe and NMe2; and two substituents on the same or adjacent carbon atoms of R5 can optionally be taken together to form a 5-6 membered ring that can be saturated or aromatic and contains 1-2 heteroatoms selected from N, O and S and can optionally be substituted with 1-2 groups independently selected from D, Me, halo, OH, oxo, O(C1-4 alkyl), NH2, C1-4 alkylamino, di(C1-4 alkyl)amino; and R6 is H, D, halo, C1-4 alkyl, or C1-4 haloalkyl; and one or more co-therapeutic agents selected from the group consisting of inhibitors of B-RAF, C-RAF, MEK, CDK4/6, SHP-2, HDAC, EGFR, MET, mTOR, PI3K and AKT.

Metadata:
- Claim Count in Document: 1.0
- Percentile: 98.0
- Lexical Diversity: 1.57143
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14527328', '14428546', '12812360', '11832208', '15672568']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7562219164296179
- 35 USC 102 Novelty (BERT): 0.5748859063667333
- Combined Prediction Score: 0.7380883154233294
- Mean Citation Score: 359.713364
- Max Citation Score: 444.24866
- Similarity Product: 431.9098964000392

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test